Thomas Wiggans appointed Executive Chairperson Jasper to host an investor webinar on January 8th at 8:00am ET to present ...
Expanding Portfolio of Mast Cell Programs with Plans to Initiate a Phase 1b/2a study in Patients with Asthma in Q4 2024 Company to Host Key Opinion Leader Webinar on the Potential of Briquilimab in ...
Blueprint Medicines’ focus on Ayvakit continues to pay off, which has ample untapped revenue potential in advanced and indolent systemic mastocytosis. Additionally, their pipeline includes other ...
For many patients with diverse and seemingly unrelated symptoms, obtaining an accurate diagnosis can take years of specialist visits and inconclusive tests. Mast cell activation syndrome, a disorder ...
This scanning electron microscopy image captures the moment where degranulating mast cells (pseudo-colored in sepia) attract and start to incorporate living neutrophils (pseudo-colored in cyan), ...
Depending on one's perspective, "mast cell activation syndrome (MCAS)" is either a relatively rare, narrowly defined severe allergic condition or a vastly under-recognized underlying cause of multiple ...
FODMAP Everyday® on MSN
How long COVID may be affecting your gut health
Third in a series of articles on COVID-19 and its effects on the gut, this article will explore “Long COVID” (also called ...
Thomas Wiggans appointed Executive Chairperson Jasper to host an investor webinar on January 8th at 8:00am ET to present updated data from the BEACON study in CSU and the open-label extension study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback